Combined Behavioral and Analgesic Trial for Fibromyalgia (COMBAT-FM)
Primary Purpose
Fibromyalgia
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Tramadol
Placebo
Cognitive Behavior Therapy for FM
Health Education
Sponsored by
About this trial
This is an interventional treatment trial for Fibromyalgia
Eligibility Criteria
Inclusion Criteria:
- Males and Females 21-70
- Diagnosis of Fibromyalgia
- Current primary care physician
- Fluent in English
Exclusion Criteria:
- Rheumatologic disorders
- Drug and alcohol abuse in the past year
- Psychiatric hospitalization in the past 6 months
- Current use of Tramadol
- Certain antidepressant and other pain medications
Sites / Locations
- University of Rochester
- University of Washington
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Placebo Comparator
Active Comparator
Sham Comparator
Arm Label
Tramadol
Placebo
Cognitive Behavior Therapy for FM
Health Education
Arm Description
Outcomes
Primary Outcome Measures
Number of Participants With a 30% Improvement in Pain or 20% Improvement in Function
The primary outcome is a reduction of at least 30% on the pain score (mean for 5-day daily pain diary) or improvement of 20% physical function (FIQR) from baseline (pre-treatment) to post-treatment. Individuals who achieve such decrease in pain or increase in function are labeled "responders."
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01598753
Brief Title
Combined Behavioral and Analgesic Trial for Fibromyalgia
Acronym
COMBAT-FM
Official Title
Phase 3 Double Blind Randomized Study Comparing Drug Treatment (Tramadol Versus Placebo) and Behavioral Health Treatments (Cognitive Behavioral Therapy Versus Health Education) for Patients With Fibromyalgia
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
July 31, 2018 (Actual)
Study Completion Date
July 31, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Washington
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a randomized control study that involves a combination of a drug treatment, behavioral health, and placebo controls.
Some participants will receive a medication approved by the Food and Drug Administration for treatment of moderate to moderately severe pain called Tramadol HC1 IR. Others will receive an inactive pill, called a placebo. There will also be 2 different types of behavioral health treatments, Cognitive-Behavior Therapy (CBT) and Health Education (HE) both of which have been recommended for the treatment of patients with FM by the American Pain Society.
There are 4 possible study treatment combinations:
Tramadol + CBT,
Tramadol + HE,
Placebo + CBT,
Placebo + HE.
Although Tramadol, CBT, and HE have been shown to have some benefits for FM patients, there have been no studies that have evaluated the combination of medication and a behavioral health treatment. The primary purpose of this study is to compare the benefits of the 4 combinations listed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
134 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Tramadol
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
Cognitive Behavior Therapy for FM
Arm Type
Active Comparator
Arm Title
Health Education
Arm Type
Sham Comparator
Intervention Type
Drug
Intervention Name(s)
Tramadol
Intervention Description
50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.
Minimum accepted dose of 200mg per day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Behavior Therapy for FM
Intervention Description
Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
Intervention Type
Behavioral
Intervention Name(s)
Health Education
Intervention Description
Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
Primary Outcome Measure Information:
Title
Number of Participants With a 30% Improvement in Pain or 20% Improvement in Function
Description
The primary outcome is a reduction of at least 30% on the pain score (mean for 5-day daily pain diary) or improvement of 20% physical function (FIQR) from baseline (pre-treatment) to post-treatment. Individuals who achieve such decrease in pain or increase in function are labeled "responders."
Time Frame
Baseline (one week prior to drug titration) to post-treatment (approximately 11 weeks after baseline).
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males and Females 21-70
Diagnosis of Fibromyalgia
Current primary care physician
Fluent in English
Exclusion Criteria:
Rheumatologic disorders
Drug and alcohol abuse in the past year
Psychiatric hospitalization in the past 6 months
Current use of Tramadol
Certain antidepressant and other pain medications
Facility Information:
Facility Name
University of Rochester
City
Rochester
State/Province
New York
Country
United States
Facility Name
University of Washington
City
Seattle
State/Province
Washington
ZIP/Postal Code
98195
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Combined Behavioral and Analgesic Trial for Fibromyalgia
We'll reach out to this number within 24 hrs